To investigate in this phase @a study ( ZENITH ) the safety , tolerability , and antiviral activity of VX-@ , a selective , non-nucleoside inhibitor of hepatitis C virus ( HCV ) NS@B polymerase , combined with various telaprevir-based regimens for treatment of genotype @ HCV .